Eckert & Ziegler stock: Q3 recovery confirms 2026 forecast
Published on 11/14/2026 at 11:33 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSQuarterly recovery shapes outlook
- Third-quarter sales rose to 79.6 million euros and adjusted EBIT increased 25 percent year on year.
- Management confirmed its 2026 targets for sales of around 320 million euros and adjusted EBIT of around 80 million euros.
- NuWays retained its BUY rating and a 21.50-euro 12-month price target after the results.
Eckert & Ziegler reported stronger third-quarter profitability on Thursday, November 12. According to the EQS release published by Deutsche Boerse, group sales reached 79.6 million euros, up from 75.3 million euros a year earlier. EBIT before special items rose to 19.3 million euros from 15.4 million euros, while net income increased to 13.1 million euros from 8.5 million euros.
Targets remain unchanged
For the first nine months, sales rose to 229.0 million euros and adjusted EBIT reached 52.6 million euros. Net income increased to 35.4 million euros, or 0.57 euros per share. The company confirmed its 2026 outlook for sales of around 320 million euros and adjusted EBIT of around 80 million euros.
The comparison is affected by 5.0 million euros of license revenue recorded in the prior-year period but not repeated in the first nine months of 2026. Excluding that effect, consolidated sales increased 4 percent and adjusted EBIT rose 14 percent. Eckert & Ziegler expects license revenue in the fourth quarter alongside continued demand for radiopharmaceutical products.
Analyst sees stronger earnings base
NuWays retained its BUY rating and a 21.50-euro 12-month price target in research published on Friday, November 13. The analyst highlighted the recovery in adjusted EBIT and continued potential in therapeutic isotopes, while pointing to a demanding fourth quarter.
Eckert & Ziegler stock traded at 15.36 euros on Lang & Schwarz at 11:30 CET on Saturday, November 14, 0.13 percent above the Xetra close of Friday, November 13, at 15.34 euros, according to De Belegger. The reported earnings recovery gives investors a clearer near-term test: fourth-quarter execution must support the confirmed annual targets.
Eckert & Ziegler company facts
- Company: Eckert & Ziegler SE
- ISIN: DE0005659700
- WKN: 565970
- Ticker: EUZ
- Latest quote: 15.36 euros on Lang & Schwarz, November 14, 2026, 11:30 CET
- Change: 0.13 percent above the Xetra close of 15.34 euros on November 13, 2026
- Index: TecDAX
German equities remain the broader market setting; see Current market reports.
